However, in view of the specific up-regulation of PDE4B in both human AAA and in a preclinical model, it could be hypothesized that selective PDE4B inhibitors might benefit AAA patients, and would constitute a promising therapeutic avenue for this disease. Here, PDE4B is linked to triple-A syndrome.